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Pasteurella multocida is primarily an opportunistic infection, most commonly of skin and soft tissue
following animal bites particularly in the elderly and immunocompromised. While invasive disease with
P. multocida has been documented in patients at high risk, such as those with organ transplants, ma-
lignancy, and cirrhosis, infections other than cellulitis associated with this pathogen are exceedingly rare
in the immunocompetent population. We report a 70 year old Caucasian female with occurrence of a
P. multocida pneumonia and resultant bacteremia in an immunocompetent host. Similar to prior case
studies, the patient presented with a history of having signiﬁcant exposure to animals at her residence.
We undertook a review of the literature for reports of disseminated P. multocida in immunocompotent
hosts in the absence of the typical presentation of cellulitis. Literature has suggested the possibility of
nasal and oropharyngeal colonization of patients with frequent interactions with domestic animals, in
whom periods of suppressed immune function may lead to activation of infection. P. multocida is
commonly susceptible to most beta-lactams, including those utilized for the treatment of community
acquired pneumonia. The utilization of macrolides should be avoided in these patients as susceptibilities
are unpredictable, however ﬂuoroquinolones maintain activity and may be an alternative therapy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pasteurella multocida is a gram-negative bacillary organism that
is commonly isolated from the oral secretions of felines and canines
[1,2]. A number of Pasteurella species have been identiﬁed
including strains such as, Pasteurella canis, Prunus avium and Pas-
teurella septica. However, P. multocida accounts for the most com-
mon infecting strain of Pasteurella in humans. In humans,
P. multocida is primarily an opportunistic infection, most commonly
of skin and soft tissue following animal bites particularly in the
elderly and immunocompromised [1]. While invasive disease with
P. multocida has been documented in patients at high risk, such as
those with organ transplants, malignancy, and cirrhosis, infections
other than cellulitis associated with this pathogen are exceedingly
rare in the immunocompetent population [3]. We report a case of a
70 year old Caucasian female presenting with a P. multocida
pneumonia, parapneumonic effusion and resultant bacteremia: þ1 904 244 4272.
ira).
Ltd. This is an open access article uwith no risk factors for invasive disease other than exposure to
domestic cats.
Case summary
A 70 year old Caucasian female presented to our emergency
department with complaints of worsening shortness of breath. She
complained of 2e3 days of productive cough, nasal congestion and
multiple episodes of diarrhea and vomiting. Her past medical his-
tory was signiﬁcant for hypertension and tobacco use. She had no
signiﬁcant surgical history or family history.
On physical exam she was in distress and appeared pale. Her
vital signs included oxygen saturation of 77% on room air, blood
pressure of 94/53mmHg, heart rate of 122 bpm, and temperature of
36.8 C. Respiratory exam revealed poor air movement with
diminished breath sounds at the bases bilaterally and no audible
wheezing or crackles.
Arterial blood gas on room air showed pH of 7.30, pCO2 of
43 mmHg, pO2 of 48 mmHg. The chemistry panel was signiﬁcant
for lactic acid 4.4 mmol/L. All other values were within normal
limits. Complete blood count showed leukocyte count of 25,000/nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and platelet count of 199,000/mm3.
A chest x-ray was performed with ﬁndings of hazy bibasilar
opacities right side greater than left. No pleural effusion or pneu-
mothorax was identiﬁed. The patient was placed on full face
noninvasive bi-level ventilation. Her oxygen saturation increased to
93%, and her shortness of breath improved. She expressed desire
not to be intubated or resuscitated.
Blood and urine cultures were obtained along with a respiratory
virus and inﬂuenza panel and urine streptococcal and legionella
antigens. Initially she received piperacillin-tazobactam and van-
comycin for empiric antibiotic coverage and was admitted to the
medical intensive care unit. Antimicrobial coverage was changed to
ceftriaxone and azithromycin given the lack of health-care associ-
ated pneumonia risk factors.
The patient's blood cultures grew Pasteurella multicoda in both
sets of bottles. The organism was sensitive to all antibiotics tested
and the patient was de-escalated to monotherapy with ceftriaxone.
All other cultures and viral panels returned negative. Upon further
questioning, the patient admitted to owning sixteen indoor cats.
She denied any recent scratches or bites that she could recall. Her
skin was fully inspected and found to be intact with no evidence
scratches or bites. Because of the absence of signs or symptoms of
scratch a tetanus shot was not administered during this admission.
By hospital day 3 noninvasive ventilation was weaned and
transitioned to venturi mask. Hemodynamics remained stable off
vasopressor support, her leukocytosis signiﬁcantly improved, and
lactic acidosis had resolved. Bilateral pleural effusions were visu-
alized on both x-ray and ultrasound with the right effusion being
more prominent than the left. Diagnostic thoracentesis was per-
formed with removal of 1000 mL of straw-colored ﬂuid. Analysis
revealed a transudate by Light's criteria and both gram stain and
culture returned negative.
By hospital day 6 she remained hypoxic requiring oxygen so the
decision was made to perform a CT angiogram to rule outTable 1
Review of P. multocida pneumonia in immunocompetent hosts.
Infection Age Past medical history Smoking history
Pneumonia [6] 75 Bronchiectasis and
diabetes
Unknown
Pneumonia [11] 60 Severe COPD 60 pack-year smokin
history
Pneumonia [12] 75 Hypertension Unknown
Paranasal disease and
pneumonia [4]
58 Asthma/COPD No, previously worke
in wood processing
Pneumonia with
bacteremia [2]
85 Structural lung disease Yes, non-current
Pneumonia with
bacteremia [7]
87 COPD, hypertension, atrial
ﬁbrillation, heart failure,
and myocardial infarction
Unknown
Paranasal disease,
pneumonia, and
bacteremia [3]
20 Diabetes insipidus Unknown
Pneumonia with
bacteremia [8]
65 Diabetes Unknown
Pneumonia with
bacteremia [9]
43 None No
Pneumonia with
bacteremia [10]
85 Epilepsy and venous
insufﬁciency
Unknown
Pneumonia with
empyema and
bacteremia [5]
85 None Unknown
S e sensitive, R e resistant, PCN e penicillin, SMX/TMP e sulfamethoxazole/trimethopripulmonary embolism as well as further visualize pulmonary pa-
renchyma. The CT ﬁndings were signiﬁcant for multifocal pneu-
monia within right middle lobe as well as right lower lobe and left
lower lobe with a moderate sized right pleural effusion. No pul-
monary embolism was found. She was able to be successfully dis-
charged homewith home oxygen and IV ceftriaxone to complete 14
days of treatment.Discussion
P. multocida, a commensal gram-negative coccobacilli, is a
commonly isolated pathogen from the oral and nasopharynx of a
number of mammals including humans. As an encapsulated path-
ogen, P. multocida expresses an inherent virulence, especially in
asplenic patients [1,4]. However, pathogenic mechanisms of the
bacteria are poorly understood as it causes a wide array of illnesses
across the animal kingdom. P. multocida disease syndromes in
humans are most commonly isolated to skin and skin structure
infections following a feline or canine bite [1]. Reports of dissemi-
nated infections in humans by P. multocida are increasing, ranging
from joint infections to meningitis [3]. Pneumonia caused by
P. multocida is extraordinarily rare in immunocompetent patients,
with most documented infections being isolated to case reports.
Disseminated infection occurs signiﬁcantly more frequently in the
immunocompromised host, with a relatively high mortality of
roughly 30% [3]. Most disseminated cases have been identiﬁed in
patients with malignancy, AIDS/HIV, liver cirrhosis or congenital
immunodeﬁciency [3e5]. Literature has suggested the possibility of
nasal and oropharyngeal colonization of patients with frequent
interactions with domestic animals, inwhom periods of suppressed
immune function may lead to activation of infection [4]. The rate of
dissemination or complication of infection was relatively common,
with 65% of the population developing bacteremia or empyema
complicating the course [3]. (Table 1)Animal interaction Susceptibility
Yes, 1 dog
No signs of scratches or bites
Genomic correlation with isolate
found in canine oropharynx
S- cefazolin
g 2 cats
No signs of scratches or bites
S- to all tested antibiotics
Yes, 1 cat
No signs of scratches or bites
S- cefazolin, chloramphenicol,
PCN, and tetracycline
d Yes, cats and rabbits S- amoxicillin/clavulanate
Yes, owned 16 cats
No signs of scratches or bites
SePCN, ampicillin and levoﬂoxacin
Yes, owned 6 cats and 1 dog
No signs of scratches or bites
S- beta-lactams, quinolones,
tetracyclines, SMX/TMP
R- macrolides, aminoglycosides
Yes, 1 cat
Some scratches but without
signs of cellulitis
SePCN, ampicillin, piperacillin,
cefotaxime, imipenem,
minocycline, levoﬂoxacin
Yes, cat
Reported scratch with signs
of cellulitis.
CT revealed interstitial
pneumonia
S- ceftriaxone
Yes, dog
No signs of scratches or bites
S- amoxicillin
Yes, cats
No signs of scratches or bites
S- amoxicillin/clavulanate
Yes 3 cats and 1 dog
No signs of scratches or bites
S- ceftriaxone, amoxicillin/clavulanate
m.
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resultant bacteremia in an immunocompetent host. Similar to prior
case studies, the patient presented with a history of having sig-
niﬁcant exposure to animals at her residence [3]. There are simi-
larities throughout all reported cases in an immunocompetent
hosts, likely signifying the presence of risk factors associated with
this infection. Patients reported in the literature almost exclusively
displayed some form of structural lung disease, diabetes mellitus,
advanced age and exposure to domesticated animals. Smoking has
been suggested to have an association with P. multocida infections,
and the patient reported in this case had a 20 year smoking history
and had recently taken up electronic cigarette use [2]. This brings to
question the role of smoking in the pathogenesis of P. multocida
pneumonia. Inhalants may have a multitude of effects on sup-
pressing the function of the mucocillary escalator or pulmonary
immune system, a pro-inﬂammatory response, direct inoculation
of bacterium, or potentially the association with structural lung
disease.
P. multocida appears to be responsive to antimicrobial therapy
and a number of antimicrobial options are available. Disseminated
infections still carry an impressive mortality rate of approximately
30% even with appropriate antimicrobial therapy; however this
may be related to the immunocompromised state of the host in
which the bacteria most commonly affects [3]. Penicillin remains
the drug of choice; however, beta-lactamase production has been
identiﬁed in some species [3,6]. The pathogen isolated in our case
was similar to those reported in the literature in immunocompe-
tent hosts, susceptible to penicillin, cephalosporins, sulfamethox-
azole/trimethoprim, levoﬂoxacin and tetracycline. Interestingly,
published cases report a number of macrolide treatment failures in
P. multocida. Given the rise in reported cases of P. multocida com-
munity acquired pneumonias, speciﬁcally in patients with struc-
tural lung disease, consideration should bemade to avoid the use of
macrolide therapy, especially as monotherapy, in patients with
regular exposure to domesticated animals [12]. Most strains
appeared to have responded favorably to a third generation ceph-
alosporin, amoxicillin/clavulanate, ampicillin/sulbactam, and ﬂuo-
roquinolones. While penicillin remains the drug of choice for
treatment of P. multocida, amoxicillin clavulanate is a suitable oral
alternative depending on the site of infection. Third generation
cephalosporins and newer ﬂuoroquinolones such as levoﬂoxacin
may be another alternative in the rare occurrence of penicillin
resistance or those patients unable to take penicillin [1e13]. Giventhe excellent bioavailability and serum concentrations of levo-
ﬂoxacin it is an attractive therapeutic option even in the presence of
bacteremia [13].
In conclusion, in patients with risk factors such as household
pets, lung disease and the advanced age with community ac-
quired pneumonia, P. multocida should be considered as a po-
tential pathogen. P. multocida can be a potentially invasive and
advanced disease complicated by bacteremia and empyema [1,4].
P. multocida is commonly susceptible to most beta-lactams,
including those utilized for the treatment of community ac-
quired pneumonia [3,6]. The utilization of macrolides should be
avoided in these patients as susceptibilities are unpredictable;
however, ﬂuoroquinolones maintain activity and may be an
alternative therapy for patients unable to receive beta-lactams or
requiring oral therapy [12].References
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